Compare Noble Corporation plc (NE) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs Novo Nordisk A/S — how do they compare? Noble Corporation plc trades at $42.37 (market cap $6.73B), while Novo Nordisk A/S trades at $38.52 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 24.6× Noble Corporation plc's market cap, and Noble Corporation plc pays the higher dividend (4.74%). Which is the better fit depends on your goals — on Pluang, investors hold Noble Corporation plc for 26 Days and Novo Nordisk A/S for 116 Days on average.
| NE | NVO | |
|---|---|---|
Market Cap | $6.73B | $165.31B |
Volume | 1,027,635 | 11,432,838 |
Sector | Energy | Health |
52-Week High | $54.37 | $63.98 |
52-Week Low | $26.70 | $35.29 |
Typical Hold Time | 26 Days | 116 Days |
Enterprise Value | $8.16B | $179.56B |
Dividend Yield | 4.74% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $40.97, down 1.16% today, with a bearish technical outlook. The stock shows mixed earnings performance with recent misses but maintains positive cash flow. Analyst consensus is divided with a $52 price target suggesting 27% upside. Recent news includes a long-term drilling contract with Tullow in Ghana, extending utilization into 2027.
The outlook remains cautious due to ongoing legal investigations and volatile earnings. While valuation appears reasonable with EV/EBITDA of 8.79, declining revenue and profit margins pose challenges. The dividend provides income support, but investors face execution risks amid mixed analyst sentiment.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
